Klin Farmakol Farm. 2016;30(4):14-18 | DOI: 10.36290/far.2016.036

Evaluation of efficacy of anti-IgE monoclonal antibody treatment not only in severe allergic asthma

Jaromír Bystroň, Beata Hutyrová
Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc
Ústav imunologie Lékařské fakulty Univerzity Palackého v Olomouci

The authors provide a summary of their current experience with anti-IgE antibody (omalizumab) treatment at their workplace as
well as in the Czech Republic. They report the results of studies in which omalizumab was used to treat allergic conditions other
than severe bronchial asthma, and present findings recorded in patients monitored in the Czech Anti-IgE Registry (CAR) in the
Czech Republic.

Keywords: omalizumab, alerhy, CAR – Czech anti-IgE register

Received: January 3, 2019; Accepted: July 25, 2019; Prepublished online: July 25, 2019; Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bystroň J, Hutyrová B. Evaluation of efficacy of anti-IgE monoclonal antibody treatment not only in severe allergic asthma. Klin Farmakol Farm. 2016;30(4):14-18. doi: 10.36290/far.2016.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kolektiv autorů: Efektivita omalizumabu v léčbě těžkého alergického astmatu v České republice - výsledky registru CAR (Czech Anti-IgE Registry).XVII. kongres České a Slovenské pneumologické a ftizeologické společnosti. Praha: Trios, 2011. 2011, Supl., s. 33. ISBN: 978-80-87118-04-7. Studia pneumologica et phthiseologica. 2011, Supl. (XVII. kongres České a Slovenské pneumologické a ftizeologické společnosti: Plzeň, 23.-25. 6. 2011), s. 33.
    2. Bystroň J. Účinnost léčby anti-IgE monoklonální protilátkou nejen u těžkého alergického astmatu (problémy, skutečnost, naděje). Alergie. 2011; 4(13): 264-267. ISSN: 1212-3536; 1212-687X (elektronická verze).
    3. Bystroň J. Biologická léčba u těžkého perzistujícího astmatu - co nám naznačují kasuistiky. Kasuistiky v alergologii, pneumologie a ORL. 2010; 1(7): 20-24.
    4. Bystroň J. Léčba anti-IgE: mýty, skutečnost, naděje. Klinická imunológia a alergológia. 2011; 1(21): 29-30. ISSN: 1335-0013.
    5. Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E. Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther 2014; 8: 197-207. Go to original source... Go to PubMed...
    6. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systemic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2014; Pract 3: 332-340. Go to original source... Go to PubMed...
    7. Cusack RP, Sahadevan A, Lane SJ. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: a real life observational study. QJM 2016; 1-4. Go to original source...
    8. Casale TB, Condemi J, LaForce C, et al. Omalizumab Seasonal Allergic Rhinitis Trial Group.Effect of omalizimab on symptoms of saesonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286: 2956-2967. Go to original source... Go to PubMed...
    9. Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J Allergy Clin Immunol 2015; 136(6): 1431-1440. Go to original source... Go to PubMed...
    10. El-Qutob D. Off-Label Uses of Omalizumab. Clin Rev Allergy Immunol 2016; 50(1): 84-96. Go to original source... Go to PubMed...
    11. Guglielmo M, Gulotta C, Mancini F, Sacchi M, Tarantini F. Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19(2): 158-159.
    12. Grundmann SA, Hemfort PB, Luger TA, Brehler R. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 2008; 121(1): 257-258. Go to original source... Go to PubMed...
    13. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131(1): 110-116. Go to original source... Go to PubMed...
    14. Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax 2011; 66(9): 824-825. Go to original source... Go to PubMed...
    15. Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K, et al. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 2013; 110(5): 387-388. Go to original source... Go to PubMed...
    16. Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007; 21(4): 428-432. Go to original source... Go to PubMed...
    17. Yalcin AD, Uçar S, Gumuslu S, Strauss LG. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1? and sCD200 in cases of Samter's syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol 2013; 35(4): 524-527. Go to original source... Go to PubMed...
    18. Yalcin AD. An overview of the effects of anti-IgE therapies. Med Sci Monit 2014; 20: 1691-1699. Go to original source... Go to PubMed...
    19. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010; 48: 318-324. Go to original source... Go to PubMed...
    20. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U; DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39(2): 271-279. Go to original source... Go to PubMed...
    21. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010; 125: 383-389. Go to original source... Go to PubMed...
    22. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010; 21: 160-165. Go to original source... Go to PubMed...
    23. Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis. 2015; 6(6): 304-313. Go to original source... Go to PubMed...
    24. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368(10): 924-935. Go to original source... Go to PubMed...
    25. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008; 29: 530-537. Go to original source... Go to PubMed...
    26. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-1225. Go to original source... Go to PubMed...
    27. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Antiimmunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013; 38: 496-500. Go to original source... Go to PubMed...
    28. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - randomized, placebo-controlled and double-blind pilot study. J Dtsch Dermatol Ges. 2010; 8: 990-998. Go to original source... Go to PubMed...
    29. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53: 338-340. Go to original source... Go to PubMed...
    30. Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immuno 2016; S0091-6749(16)30615-30617. Go to original source... Go to PubMed...
    31. Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchanian V, Weidinger S, Mempel M, Ring J, Ollert M. Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab. Acta Derm Venereol 2016; 96(1): 72-76. Go to original source... Go to PubMed...
    32. Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Fölster-Holst R, et al. Increased efficacy of omalizumab in atopic dermatitis patiens with wild-type filaggrin status and higher levels od phosphatidylcholines. Allergy 2014; 69: 132-135. Go to original source... Go to PubMed...
    33. Umetsu DT, Rachid R, Schneider LC. Oral immunotherapy and anti-IgE antibody treatment for food allergy. World Allergy Organ J 2015; 8(1): 20. Go to original source... Go to PubMed...
    34. Leung DY, Sampson HA, Yunginger JW, Burks AWJr, Schneider LC, Wortel CH,et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348(11): 986-993. Go to original source... Go to PubMed...
    35. Bauer RN, Manohar M, Singh AM, Jay DC, Nadeau KC. The future of biologics: applications for food allergy. J Allergy Clin Immunol 2015; 135: 312-323. Go to original source... Go to PubMed...
    36. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 2013; 132(6): 1368-1374. Go to original source... Go to PubMed...
    37. Nadeau K, Schneider L, Hoyte E, Borras I, Umetsu D. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011; 127: 1722-1724. Go to original source... Go to PubMed...
    38. Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, Plaut M, Sampson HA. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol. 2016; 137(4): 1103-1110. Go to original source... Go to PubMed...
    39. Bégin P, Dominguez T, Wilson SP, Bacal L, Mehrotra AB, Trela A, Tavassoli M, Hoyte E, O'Riordan G, Blakemore A, Seki S, Hamilton RG, Nadeau KC. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol. 2014; 10(1): 7. Go to original source... Go to PubMed...
    40. Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, Metcalfe DD, Mannon PJ, Prussin C. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007; 120(3): 594-601. Go to original source... Go to PubMed...
    41. Rocha R, Vitor AB, Trindade E, Lima R, TavaresM, Lopes J et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 2011; 170(11): 1471-1474. Go to original source... Go to PubMed...
    42. Collins J, Devos G, Hudes G, Rosenstreich D. Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy 2012; 5: 65-70. Go to original source... Go to PubMed...
    43. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, Trunet P. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113(2): 360-361. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.